Differences in maternal group B Streptococcus screening rates in Latin American countries.

Vaccine

Yale Institute of Global Health, Department of Medicine (Section of Infectious Diseases), Yale School of Medicine. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 333 Cedar St, New Haven, CT 06510, USA. Electronic address:

Published: July 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To determine rates and results of maternal Group B streptococcus (GBS) screening during pregnancy and identify sociodemographic characteristics associated with GBS screening in Latin American countries.

Background: GBS is a primary cause of morbidity and mortality in neonates and is prevented by screening pregnant women for GBS before delivery and intrapartum antibiotic treatment. Yet, data regarding national GBS screening practices and the epidemiology of maternal GBS colonization in Latin America are limited.

Methods: We conducted a retrospective observational study using de-identified records of pregnant women in six Latin American countries from a regional database. 460,328 collected from January 1, 2009 through December 31, 2012 met study criteria and were included. Maternal screening rates for GBS were determined, association of demographic variables (ethnicity, age, education level, and civil status) with maternal GBS screening was determined using logistic regression, odds ratios were calculated comparing incidence of adverse neonatal outcomes (sepsis, pneumonia, and meningitis) between countries with high and low rates of GBS screening, maternal GBS colonization prevalence was determined by year and association of demographic variables with maternal GBS colonization was determined using logistic regression.

Results: Maternal GBS screening was less than 15% in each country, except Uruguay which screened greater than 65% of women. The final regression model examining maternal screening rates and demographic variables included the covariates ethnicity, maternal age group, education level and civil status. Countries with lower rates of maternal GBS screening had increased odds of neonatal sepsis [OR 23.3; 95% CI (15.2-35.9)] and pneumonia [OR 19.9; 95% CI (12.1-32.6)]. In Uruguay, GBS prevalence over the study period was 18.5%. Black women, older women and women without a primary education had higher rates of GBS colonization (21.3%, 20.4% and 21.9% respectively).

Conclusions: Our study highlights the need for national policy and investments to increase maternal GBS screening and better understand the prevalence of maternal GBS colonization in Latin America. Further research on the burden of neonatal GBS disease within Latin America is needed to inform the introduction of a maternal GBS vaccine, when available.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2020.10.082DOI Listing

Publication Analysis

Top Keywords

maternal gbs
36
gbs screening
32
gbs colonization
20
gbs
19
maternal
13
screening
12
screening rates
12
latin american
12
latin america
12
rates gbs
12

Similar Publications

Guillain-Barré syndrome (GBS), a serious acute neurological disorder that can occur during pregnancy and the postpartum period, poses significant risks to maternal health. Severe cases may rapidly progress to generalized paralysis or life-threatening complications, underscoring the urgency of early rehabilitation interventions to mitigate acute sequelae. This report details the rehabilitation journey of a 27-year-old female diagnosed with GBS following cesarean delivery at 36 weeks of gestation.

View Article and Find Full Text PDF

Background: The aim of this study was to investigate perspectives on participation in a Group B Streptococcus (GBS) maternal vaccine trial among pregnant women, their partners, family members, friends and other stakeholders in Kampala, Uganda.

Methods: We conducted focus group discussions, in-depth interviews and key informant interviews from October 2022 to February 2023 with 56 participants: 36 pregnant or breastfeeding women, 5 women not in the trial, 5 partners of women in trial, 5 healthcare workers, and 5 community stakeholders. This cross-sectional study was embedded within a GBS maternal vaccine trial conducted at the national referral hospital.

View Article and Find Full Text PDF

: Maternal immunization is highly recommended, particularly in developed countries. However, its awareness among pregnant women in Japan remains low. This study aimed to assess the awareness and attitudes toward maternal immunization among pregnant women in Japan and to identify the factors that may promote its acceptance.

View Article and Find Full Text PDF

Objective: To investigate the relationship between Group B Streptococcus (GBS) infection in pregnant women and adverse pregnancy events (APEs), as well as serum inflammatory factors (IFs) and coagulation parameters.

Methods: A retrospective analysis was conducted on 2,200 late-pregnancy women who delivered at Maternal and Child Health Hospital from March 2020 to January 2023. Data on GBS infection, serotyping, immunofluorescence, coagulation parameters, and APEs were collected.

View Article and Find Full Text PDF

Group B Streptococcus (GBS) is a bacterial pathogen associated with significant morbidity and mortality in pregnant women and infants, particularly in resource-limited settings. A hexavalent vaccine candidate in development incorporates the capsular polysaccharides (CPSs) from the most prevalent serotypes: Ia, Ib, II, III, IV, and V. Vaccine production is facilitated by a standardized CPS purification process.

View Article and Find Full Text PDF